Sooma Medical develops non-invasive brain stimulation devices for psychiatric and neurological disorders, working closely with medical experts to create effective treatment solutions. The company's devices comply with ISO 13485 and MDSAP quality management standards. Its depression therapy is available in more than 35 countries worldwide, and more than 20,000 patients have used these treatments to date. Led by CEO Tuomas Neuvonen and based in Helsinki, Finland, Sooma emphasizes drug-free, at-home accessibility for patients underserved by medication or with limited access to psychotherapy. The company intends to use the €5M in funding to accelerate product development and continue rapid expansion into new and existing markets. Sooma positions its devices as accessible, clinician-aligned alternatives aimed at expanding care options for people with depression. Sooma Medical develops, manufactures and markets a non-invasive brain stimulation therapy for neurological and psychiatric disorders, notably depression and chronic pain. Its depression technology modulates neuronal activation in frontal brain areas and is designed for patient self-administration at home. Treatment consists of one 30-minute session per day for about three weeks and is reported to have no serious or systemic side effects. The company works with experts in psychiatry and clinical neurophysiology and is supported by a board and advisors with medical and healthcare technology experience. Sooma was established in 2013 and is led by CEO Tuomas Neuvonen. financially, the company completed a €1.25m funding package comprising equity and a public grant.

Total raised

$7M

Funding rounds

3

Latest round

Equity

Latest activity

Mar 2024